<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2019-1-76-80</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-859</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL &amp; EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Сравнительные клинические исследования эффективности применения плазмафереза в сочетании с озонотерапией в профилактике рецидивов офтальмогерпеса</article-title><trans-title-group xml:lang="en"><trans-title>Comparative Clinical Study the Effectiveness of Plasmapheresis with Ozone Therapy in the Prevention of Ocular Herpes Recurrence</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гулиева</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Guliyeva</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, зав. отделением инфекционных болезней глаза и хирургии роговицыул. Джавадхана, 32/15, Баку, AZ1114, Азербайджанская республика</p></bio><bio xml:lang="en"><p>PhD, head Department of Infectious Diseases of the Eye and Cornea SurgeryJavadkhan str., 32/15, Baku, AZ 1114, Azerbaijan</p></bio><email xlink:type="simple">minaragamid@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный центр офтальмологии им. Акад. Зарифы Алиевой Министерства здравоохранения Азербайджанской республики</institution><country>Азербайджан</country></aff><aff xml:lang="en"><institution>National Centre of Ophthalmology named after Acad. Zarifa Aliyeva Ministry of Health Of Azerbaijan Republic</institution><country>Azerbaijan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>29</day><month>03</month><year>2019</year></pub-date><volume>16</volume><issue>1</issue><fpage>76</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гулиева М.Г., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Гулиева М.Г.</copyright-holder><copyright-holder xml:lang="en">Guliyeva M.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/859">https://www.ophthalmojournal.com/opht/article/view/859</self-uri><abstract><p>Цель: изучение клинической эффективности плазмафереза в сочетании с озонотерапией в профилактике рецидивов офтальмогерпеса. Пациенты и методы. Всего под наблюдением находилось 108 больных с рецидивирующими формами офтальмогерпеса (герпетический кератит, кератоувеит, увеит). В исследовании принимали участие 56 мужчин и 52 женщины, возраст колебался от 37 до 62 лет (47,6 ± 11,5). Число включенных в основную группу больных составило 54 (54 глаза), в группу сравнения — 54 больных (54 глаза). Результаты. Из 54 человек основной группы, проходивших курс противорецидивной терапии методом плазмафереза в сочетании с лечебным озоном в комбинации с традиционным лечением, выраженный терапевтический эффект зарегистрирован у 48 (88,9 %) пациентов, частичный терапевтический эффект (снижение частоты рецидивов) наблюдался у 6 (11,1 %) больных, отсутствие эффекта не регистрировалось ни у одного больного. В контрольной группе из 54 больных, проходивших курс противорецидивной терапии методом плазмафереза в комбинации с традиционным лечением, выраженный терапевтический эффект (отсутствие обострений) наблюдался у 31 (57,4 %) больного, частичный терапевтический эффект (снижение частоты рецидивов) — у 17 (31,5 %) больных, отсутствие эффекта — у 6 (11,1 %). Выводы. Для профилактики рецидивов офтальмогерпеса и достижения оптимального результата противорецидивной терапии у больных с рецидивирующим офтальмогерпесом показано одновременно с началом стандартного противогерпетического лечения проводение курсов плазмафереза с озонотерапией и продолжение его в качестве монотерапии после окончания лечения.</p></abstract><trans-abstract xml:lang="en"><p>The purpose. To study the clinical efficacy of plasmapheresis in combination with ozone therapy in the prevention of ocular herpes recurrence. Patients and methods. There were 108 patients with relapsing forms of eye herpes (herpes keratitis, keratouveitis, uveitis) under our observation. 56 men and 52 women, aged between 37 and 62 old (47,6 ± 11,5) were involved into the research. The number of patients included into the main group were 54 (54 eyes), and also 54 patients (54 eyes) were in the comparison group. Results. In the main group, the patients undergone a course of anti — relapse therapy with plasmapheresis in combination with therapeutic ozone in combination with traditional treatment from 54 persons — the expressed therapeutic effect was registered in 48-and (88.8 %) patients, the partial therapeutic effect (decrease in the frequency of relapses) was observed in 6 (11.1 %) patients, the absence of effect was not registered in any patient. In the control group, consisting of 54 patients, which undergone anti-relapse therapy with plasmapheresis in combination with traditional treatment, expressed therapeutic effect (no exacerbations) was observed in 31 (57.4 %) patients, a partial therapeutic effect (decrease in the frequency of relapses) was observed in 17 (31.5 %) patients, and the absence of effect — in 6 (11.1 %) patients. Conclusions. For prevention of ophthalmic herpes recurrence and optimal results of anti-relapse therapy of patients with recurrent ophthalmic herpes were shown concurrently with the beginning of the standard antiherpetic treatment courses of plasmapheresis with ozone therapy and spend it as monotherapy at the end of treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рецидивирующий офтальмогерпес</kwd><kwd>профилактика рецидивов</kwd><kwd>плазмаферез</kwd><kwd>озонотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>recurrent eye herpes</kwd><kwd>prevention of recurrence</kwd><kwd>plasmapheresis</kwd><kwd>ozone therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Центр СМИ Всемирной организации здравоохранения. www.who.int/mediacentre/news/releases/2015/herpes/ru/</mixed-citation><mixed-citation xml:lang="en">Media center WHO. www.who.int/mediacentre/news/releases/2015/herpes/ru/</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Biswas P.S., Rouse B.T. Early events in HSV keratitis — setting the stage for a blinding disease. Microbes-Infect. 2005;7(4):799–810. DOI: 10.1016/j.micinf.2005.03.003</mixed-citation><mixed-citation xml:lang="en">Biswas P.S., Rouse B.T. Early events in HSV keratitis — setting the stage for a blinding disease. Microbes-Infect. 2005;7(4):799–810. DOI: 10.1016/j.micinf.2005.03.003</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufman H.E. Persistent impairment of quality of life in patients with herpes simplex keratitis. Ophthalmology. 2017;124:160–169. 2017 Sep;124(9):e68. DOI: 10.1016/j.ophtha.2017.03.065</mixed-citation><mixed-citation xml:lang="en">Kaufman H.E. Persistent impairment of quality of life in patients with herpes simplex keratitis. Ophthalmology. 2017;124:160–169. 2017 Sep;124(9):e68. DOI: 10.1016/j.ophtha.2017.03.065</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pan D., Kaye S.B., Hopkins M., Kirwan R., Hart I.J., Coen D.M. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis. 2014;1;209(3):345–349. DOI: 10.1093/infdis/jit437. Epub 2013 Aug 14.</mixed-citation><mixed-citation xml:lang="en">Pan D., Kaye S.B., Hopkins M., Kirwan R., Hart I.J., Coen D.M. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis. 2014;1;209(3):345–349. DOI: 10.1093/infdis/jit437. Epub 2013 Aug 14.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Wang L., Wu N., Ma X., Xu J. Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis. Chin Med J (Engl). 2015;Jan 5;128(1):46–50. DOI: 10.4103/0366-6999.147808. Erratum in: Chin Med J</mixed-citation><mixed-citation xml:lang="en">Wang X., Wang L., Wu N., Ma X., Xu J. Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis. Chin Med J (Engl). 2015;Jan 5;128(1):46–50. DOI: 10.4103/0366-6999.147808. Erratum in: Chin Med J (Engl). 2016 Jan 5;129(1):115. Chin Med J (Engl). 2015 Feb 5;128(3):426.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">(Engl). 2016 Jan 5;129(1):115. Chin Med J (Engl). 2015 Feb 5;128(3):426.</mixed-citation><mixed-citation xml:lang="en">Moshetova L.K., Chernakova G.M., Abayeva M.R. Anti-relapse efficacy of Amixin in combination with antiherpetic vaccine in patients with herpetic keratitis. Annals of Ophthalmology = Vestnik oftal’mologii. 2004;120(3):22–24 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Мошетова Л.К., Чернакова Г.М., Абаева М.Р. Противорецидивная эффективность Амиксина в сочетании с противогерпетической вакциной у больных с герпетическим кератитом. Вестник офтальмологии. 2004;120(3):22–24.</mixed-citation><mixed-citation xml:lang="en">Mallok A., Vaillant J.D., Soto M.T., Viebahn-Hänsler R., Viart Mde L., Pérez A.F., Cedeño R.I., Fernández O.S. Ozone protective effects against PTZ-induced generalized seizures are mediated by reestablishment of cellular redox balance and A1 adenosine receptors. Neurol Res. 2015 Mar;37(3):204–210. DOI: 10.1179/1743132814Y.0000000445</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mallok A., Vaillant J.D., Soto M.T., Viebahn-Hänsler R., Viart Mde L., Pérez A.F., Cedeño R.I., Fernández O.S. Ozone protective effects against PTZ-induced generalized seizures are mediated by reestablishment of cellular redox balance and A1 adenosine receptors. Neurol Res. 2015 Mar;37(3):204–210. DOI: 10.1179/1743132814Y.0000000445</mixed-citation><mixed-citation xml:lang="en">Vaillant J.D., Fraga A., Díaz M.T., Mallok A., Viebahn-Hänsler R., Fahmy Z., Barberá A., Delgado L., Menéndez S., Fernández O.S. Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. Eur J Pharmacol. 2013 Aug 15;714(1–3):318–324. DOI: 10.1016/j.ejphar. 2013.07.034</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vaillant J.D., Fraga A., Díaz M.T., Mallok A., Viebahn-Hänsler R., Fahmy Z., Barberá A., Delgado L., Menéndez S., Fernández O.S. Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. Eur J Pharmacol. 2013 Aug 15;714(1–3):318–324. DOI: 10.1016/j.ejphar. 2013.07.034</mixed-citation><mixed-citation xml:lang="en">Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017;Oct 17;7(3):212–219. DOI: 10.4103 / 2045-9912.215752. eCollection 2017 Jul-Sep.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017;Oct 17;7(3):212–219. DOI: 10.4103 / 2045-9912.215752. eCollection 2017 Jul-Sep.</mixed-citation><mixed-citation xml:lang="en">Zeng J., Lu J. Mechanisms of action involved in ozone-therapy in skin diseases. Int Immunopharmacol. 2018 Mar;56:235–241. DOI: 0.1016/j.intimp. 2018.01.040</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng J., Lu J. Mechanisms of action involved in ozone-therapy in skin diseases. Int Immunopharmacol. 2018 Mar;56:235–241. DOI: 0.1016/j.intimp. 2018.01.040</mixed-citation><mixed-citation xml:lang="en">Shamim T. Ozone therapy in dentistry: revisited. Med Gas Res. 2018;Jan 22;7(4):278. DOI: 10.4103/2045-9912.222453. eCollection 2017 Oct-Dec.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shamim T. Ozone therapy in dentistry: revisited. Med Gas Res. 2018;Jan 22;7(4):278. DOI: 10.4103/2045-9912.222453. eCollection 2017 Oct-Dec.</mixed-citation><mixed-citation xml:lang="en">Borrelli E., Diadori A., Zalaffi A., Bocci V. Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study Int J Ophthalmol. 2012;5(6):708–713. DOI: 10.3980/j.issn.2222-3959.2012.06.11</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Borrelli E., Diadori A., Zalaffi A., Bocci V. Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study Int J Ophthalmol. 2012;5(6):708–713. DOI: 10.3980/j.issn.2222-3959.2012.06.11</mixed-citation><mixed-citation xml:lang="en">Borrelli E., Diadori A., Zalaffi A., Bocci V. Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study Int J Ophthalmol. 2012;5(6):708–713. DOI: 10.3980/j.issn.2222-3959.2012.06.11</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
